Literature DB >> 18187545

A metabolomic perspective of melatonin metabolism in the mouse.

Xiaochao Ma1, Chi Chen, Kristopher W Krausz, Jeffrey R Idle, Frank J Gonzalez.   

Abstract

Metabolism of melatonin (MEL) in mouse was evaluated through a metabolomic analysis of urine samples from control and MEL-treated mice. Besides identifying seven known MEL metabolites (6-hydroxymelatonin glucuronide, 6-hydroxymelatonin sulfate, N-acetylserotonin glucuronide, N-acetylserotonin sulfate, 6-hydroxymelatonin, 2-oxomelatonin, 3-hydroxymelatonin), principal components analysis of urinary metabolomes also uncovered seven new MEL metabolites, including MEL glucuronide, cyclic MEL, cyclic N-acetylserotonin glucuronide, cyclic 6-hydroxymelatonin; 5-hydroxyindole-3-acetaldehyde, di-hydroxymelatonin and its glucuronide conjugate. However, N(1)-acetyl-N(2)-formyl-5-methoxy-kynuramine and N(1)-acetyl-5-methoxy-kynuramine, known as MEL antioxidant products, were not detected in mouse urine. Metabolite profiling of MEL further indicated that 6-hydroxymelatonin glucuronide was the most abundant MEL metabolite in mouse urine, which comprised 75, 65, and 88% of the total MEL metabolites in CBA, C57/BL6, and 129Sv mice, respectively. Chemical identity of 6-hydroxymelatonin glucuronide was confirmed by deconjugation reactions using beta-glucuronidase and sulfatase. Compared with wild-type and CYP1A2-humanized mice, Cyp1a2-null mice yielded much less 6-hydroxymelatonin glucuronide (approximately 10%) but more N-acetylserotonin glucuronide (approximately 195%) and MEL glucuronide (approximately 220%) in urine. In summary, MEL metabolism in mouse was recharacterized by using a metabolomic approach, and the MEL metabolic map was extended to include seven known and seven novel pathways. This study also confirmed that 6-hydroxymelatonin glucuronide was the major MEL metabolite in the mouse, and suggested that there was no interspecies difference between humans and mice with regard to CYP1A2-mediated metabolism of MEL, but a significant difference in phase II conjugation, yielding 6-hydroxymelatonin glucuronide in the mouse and 6-hydroxymelatonin sulfate in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187545      PMCID: PMC2276702          DOI: 10.1210/en.2007-1412

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  40 in total

1.  The identification of [2-(14)C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine metabolites in humans.

Authors:  M A Malfatti; K S Kulp; M G Knize; C Davis; J P Massengill; S Williams; S Nowell; S MacLeod; K H Dingley; K W Turteltaub; N P Lang; J S Felton
Journal:  Carcinogenesis       Date:  1999-04       Impact factor: 4.944

Review 2.  Human hepatocytes as a key in vitro model to improve preclinical drug development.

Authors:  G Fabre; J Combalbert; Y Berger; J P Cano
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

3.  Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study.

Authors:  P N Suresh Kumar; Chittaranjan Andrade; Savita G Bhakta; Nagendra M Singh
Journal:  J Clin Psychiatry       Date:  2007-02       Impact factor: 4.384

4.  Transcription factor dynamics and neuroendocrine signalling in the mouse pineal gland: a comparative analysis of melatonin-deficient C57BL mice and melatonin-proficient C3H mice.

Authors:  C von Gall; A Lewy; C Schomerus; B Vivien-Roels; P Pevét; H W Korf; J H Stehle
Journal:  Eur J Neurosci       Date:  2000-03       Impact factor: 3.386

5.  The isolation, purification, and characterisation of the principal urinary metabolites of melatonin.

Authors:  A M Leone; P L Francis; R E Silman
Journal:  J Pineal Res       Date:  1987       Impact factor: 13.007

6.  An enzyme immunoassay for 6-sulphatoxy-melatonin in human urine.

Authors:  J F Peniston-Bird; W L Di; C A Street; R Edwards; J A Little; R E Silman
Journal:  J Pineal Res       Date:  1996-03       Impact factor: 13.007

7.  Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism.

Authors:  H C Liang; H Li; R A McKinnon; J J Duffy; S S Potter; A Puga; D W Nebert
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

8.  Genetic control of melatonin synthesis in the pineal gland of the mouse.

Authors:  S Ebihara; T Marks; D J Hudson; M Menaker
Journal:  Science       Date:  1986-01-31       Impact factor: 47.728

9.  Rapid and simple synthesis for the sulphate esters of 6-hydroxy-melatonin and N-acetyl-serotonin.

Authors:  A M Leone; P L Francis; B McKenzie-Gray
Journal:  J Pineal Res       Date:  1988       Impact factor: 13.007

10.  A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation.

Authors:  D X Tan; L C Manchester; R J Reiter; B F Plummer; L J Hardies; S T Weintraub; A M Shepherd
Journal:  Biochem Biophys Res Commun       Date:  1998-12-30       Impact factor: 3.575

View more
  21 in total

Review 1.  Xenobiotic metabolism: a view through the metabolometer.

Authors:  Andrew D Patterson; Frank J Gonzalez; Jeffrey R Idle
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

Review 2.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

3.  Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice.

Authors:  Hong-Wu Shen; Ai-Ming Yu
Journal:  Drug Metab Lett       Date:  2009-12

4.  Analysis of N1-acetyl-N2-formyl-5-methoxykynuramine/N1-acetyl-5-methoxy-kynuramine formation from melatonin in mice.

Authors:  Sida Niu; Feng Li; Dun-Xian Tan; Lirong Zhang; Jeffrey R Idle; Frank J Gonzalez; Xiaochao Ma
Journal:  J Pineal Res       Date:  2010-05-27       Impact factor: 13.007

5.  Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.

Authors:  Fei Li; Andrew D Patterson; Constance C Höfer; Kristopher W Krausz; Frank J Gonzalez; Jeffrey R Idle
Journal:  Biochem Pharmacol       Date:  2010-06-10       Impact factor: 5.858

Review 6.  Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Cezary Skobowiat; Blazej Zbytek; Radomir M Slominski; Jeffery D Steketee
Journal:  Adv Anat Embryol Cell Biol       Date:  2012       Impact factor: 1.231

Review 7.  Potential role of CYP1B1 in the development and treatment of metabolic diseases.

Authors:  Fei Li; Weifeng Zhu; Frank J Gonzalez
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

8.  Sleep and circadian abnormalities in patients with cirrhosis: features of delayed sleep phase syndrome?

Authors:  Sara Montagnese; Benita Middleton; Ali R Mani; Debra J Skene; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2009-09       Impact factor: 3.584

9.  Bedaquiline metabolism: enzymes and novel metabolites.

Authors:  Ke Liu; Feng Li; Jie Lu; Shinlan Liu; Kenneth Dorko; Wen Xie; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2014-02-10       Impact factor: 3.922

10.  N-acetyl serotonin derivatives as potent neuroprotectants for retinas.

Authors:  Jianying Shen; Kanika Ghai; Pradoldej Sompol; Xia Liu; Xuebing Cao; P Michael Iuvone; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.